{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:04Z","timestamp":1791335644301,"version":"4.3.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180882"],"award-info":[{"award-number":["U10CA180882"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180866"],"award-info":[{"award-number":["U10CA180866"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180790"],"award-info":[{"award-number":["U10CA180790"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189872"],"award-info":[{"award-number":["UG1CA189872"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Preclinical and clinical data have shown promise in using antiangiogenic agents to treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate the efficacy and toxicity of single-agent pazopanib in patients with MPM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Patients with MPM who had received 0\u20131 prior chemotherapy regimens were eligible to receive pazopanib at a dose of 800 mg daily. The primary endpoint was progression-free survival rate at 6 months (PFS6), with a preplanned interim analysis for futility. Secondary endpoints included overall survival (OS), PFS, adverse events assessment and clinical benefit (complete response, partial response [PR], and stable disease [SD]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-four evaluable patients were enrolled, with a median age of 73\u2009years (49\u201384). The trial was closed early because of lack of efficacy at the preplanned interim analysis. Only 8 patients (28.6%; 95% confidence interval [CI], 13.2\u201348.7%) in the first 28 evaluable were progression-free at 6 months. PFS6 was 32.4% (95% CI, 17.4\u201350.5). There were 2 PR (5.9%) and 16 SD (47.1%). The overall median PFS and OS were 4.2 months (95% CI, 2.0\u20136.0) and 11.5 months (95% CI: 5.3\u201318.2), respectively. The median PFS and OS for the previously untreated patients was 5.4 months (95% CI, 2.7\u20138.5) and 16.6 months (95% CI, 6.6\u201330.6), respectively; and 2.0 months (95% CI, 1.3\u20134.2) and 5.0 months (95% CI: 3.0\u201311.9), respectively, for the previously treated patients. Grade 3 or higher adverse events were observed in 23 patients (67.6%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Single-agent pazopanib was poorly tolerated in patients with MPM. The primary endpoint of PFS6 was not achieved in the current study. ClinicalTrials.gov \u00a0identification number. NCT00459862.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Single-agent pazopanib did not meet its endpoint in this phase II trial in malignant mesothelioma. Pazopanib is well tolerated in mesothelioma patients with a manageable toxicity profile. There is a need to better identify signals of angiogenesis that can be targeted in mesothelioma. Encouraging findings in frontline treatment warrant further investigations in combination with chemotherapy or immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0574","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T12:07:53Z","timestamp":1581336473000},"page":"523-531","source":"Crossref","is-referenced-by-count":4,"title":["A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)"],"prefix":"10.1093","volume":"25","author":[{"given":"Kaushal","family":"Parikh","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"John Theurer Cancer Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra J.","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Allen-Ziegler","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandt","family":"Esplin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina D.","family":"Tan","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Marchello","sequence":"additional","affiliation":[{"name":"Montana Cancer Consortium, Billings, Montana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R.","family":"Molina","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"key":"2021122510341395900_onco13201-bib-0001","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: The standard of care and challenges for future management","volume":"78","author":"van Meerbeeck","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122510341395900_onco13201-bib-0002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0b013e328341ccdd","article-title":"Targeted therapies in malignant pleural mesothelioma: A review of clinical studies","volume":"22","author":"Greillier","year":"2011","journal-title":"Anticancer Drugs"},{"key":"2021122510341395900_onco13201-bib-0003","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"European Respiratory Society\/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"2021122510341395900_onco13201-bib-0004","first-page":"4833","article-title":"Expression of vascular endothelial growth factor in malignant mesothelioma","volume":"26","author":"Aoe","year":"2006","journal-title":"Anticancer Res"},{"key":"2021122510341395900_onco13201-bib-0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"2021122510341395900_onco13201-bib-0006","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/138945009789753200","article-title":"Molecular targets in malignant pleural mesothelioma treatment","volume":"10","author":"Pasello","year":"2009","journal-title":"Curr Drug Targets"},{"key":"2021122510341395900_onco13201-bib-0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","article-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","volume":"105","author":"Hirayama","year":"2011","journal-title":"Respir Med"},{"key":"2021122510341395900_onco13201-bib-0008","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"key":"2021122510341395900_onco13201-bib-0009","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"2021122510341395900_onco13201-bib-0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2021122510341395900_onco13201-bib-0011","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","article-title":"The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122510341395900_onco13201-bib-0012","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.seminoncol.2005.02.010","article-title":"New agents in the management of advanced mesothelioma","volume":"32","author":"Vogelzang","year":"2005","journal-title":"Semin Oncol"},{"key":"2021122510341395900_onco13201-bib-0013","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122510341395900_onco13201-bib-0014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrclinonc.2010.83","article-title":"Targeted therapies: Pazopanib: Carving a niche in a crowded therapeutic landscape","volume":"7","author":"Pal","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122510341395900_onco13201-bib-0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1634\/theoncologist.2009-0225","article-title":"Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer","volume":"15","author":"Scagliotti","year":"2010","journal-title":"The Oncologist"},{"key":"2021122510341395900_onco13201-bib-0016","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122510341395900_onco13201-bib-0017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"The Oncologist"},{"key":"2021122510341395900_onco13201-bib-0018","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrendo.2011.141","article-title":"Multikinase inhibitors: A new option for the treatment of thyroid cancer","volume":"7","author":"Gild","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2021122510341395900_onco13201-bib-0019","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-10-3409","article-title":"A Phase II study of pazopanib in Asian patients with recurrent\/metastatic nasopharyngeal carcinoma","volume":"17","author":"Lim","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122510341395900_onco13201-bib-0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122510341395900_onco13201-bib-0021","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0197-2456(00)00115-X","article-title":"A three-outcome design for phase II clinical trials","volume":"22","author":"Sargent","year":"2001","journal-title":"Control Clin Trials"},{"key":"2021122510341395900_onco13201-bib-0022","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122510341395900_onco13201-bib-0023","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/cncr.23313","article-title":"A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: A North Central Cancer Treatment Study, N0021","volume":"112","author":"Okuno","year":"2008","journal-title":"Cancer"},{"key":"2021122510341395900_onco13201-bib-0024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation for incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2021122510341395900_onco13201-bib-0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2021122510341395900_onco13201-bib-0026","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0167-4781(95)00196-4","article-title":"Regulation of differential expression of platelet-derived growth factor \u03b1- and \u03b2-receptor mRNA in normal and malignant human mesothelial cell lines","volume":"1305","author":"Langerak","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"2021122510341395900_onco13201-bib-0027","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0960-7404(93)90012-N","article-title":"Differential expression of platelet derived growth factor-\u03b2 in malignant mesothelioma: A clue to future therapies?","volume":"2","author":"Pogrebniak","year":"1993","journal-title":"Surg Oncol"},{"key":"2021122510341395900_onco13201-bib-0028","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1118\/1.3525836","article-title":"Computerized segmentation and measurement of malignant pleural mesothelioma","volume":"38","author":"Sensakovic","year":"2011","journal-title":"Med Phys"},{"key":"2021122510341395900_onco13201-bib-0029","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2007.07.012","article-title":"Assessment of tumor response in malignant pleural mesothelioma","volume":"33","author":"Ceresoli","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"2021122510341395900_onco13201-bib-0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.drup.2011.04.004","article-title":"Translational imaging endpoints to predict treatment response to novel targeted anticancer agents","volume":"14","author":"Serkova","year":"2011","journal-title":"Drug Resist Updat"},{"issue":"suppl","key":"2021122510341395900_onco13201-bib-0031","article-title":"Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage","volume":"49","author":"Fennell","year":"2005","journal-title":"Lung Cancer"},{"key":"2021122510341395900_onco13201-bib-0032","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Herndon JE 2nd et al; Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122510341395900_onco13201-bib-0033","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510341395900_onco13201-bib-0034","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"2021122510341395900_onco13201-bib-0035","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2021122510341395900_onco13201-bib-0036","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: A phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"S2","key":"2021122510341395900_onco13201-bib-0037","article-title":"Vatalanib in patients with previously untreated advanced malignant mesothelioma: Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)","volume":"49","author":"Jahan","year":"2005","journal-title":"Lung Cancer"},{"key":"2021122510341395900_onco13201-bib-0038","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2021122510341395900_onco13201-bib-0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"2021122510341395900_onco13201-bib-0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"2021122510341395900_onco13201-bib-0041","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1078-0432.CCR-10-1603","article-title":"Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis","volume":"17","author":"Gril","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122510341395900_onco13201-bib-0042","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1634\/theoncologist.2010-0095","article-title":"Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2010","journal-title":"The Oncologist"},{"key":"2021122510341395900_onco13201-bib-0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2011.02.041","article-title":"Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells","volume":"78","author":"Li","year":"2011","journal-title":"Urology"},{"key":"2021122510341395900_onco13201-bib-0044","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1535-7163.MCT-09-0967","article-title":"Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer","volume":"9","author":"Merritt","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2021122510341395900_onco13201-bib-0045","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1158\/1078-0432.CCR-11-0078","article-title":"Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor","volume":"17","author":"Kumar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122510341395900_onco13201-bib-0046","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-10-0232","article-title":"The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo","volume":"16","author":"Paesler","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122510341395900_onco13201-bib-0047","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1593\/tlo.09271","article-title":"Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: A molecular imaging study","volume":"3","author":"Blankenberg","year":"2010","journal-title":"Transl Oncol"},{"key":"2021122510341395900_onco13201-bib-0048","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"2021122510341395900_onco13201-bib-0049","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-018-3624-6","article-title":"Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma","volume":"82","author":"Fruehauf","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122510341395900_onco13201-bib-0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2021122510341395900_onco13201-bib-0051","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122510341395900_onco13201-bib-0052","article-title":"Final analysis of a multi-center, double-blind, placebo-controlled, randomized, phase II trial of gemcitabine\/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)","volume":"25","author":"Karrison","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510341395900_onco13201-bib-0053","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-09-2533","article-title":"Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib","volume":"70","author":"Nikolinakos","year":"2010","journal-title":"Cancer Res"},{"key":"2021122510341395900_onco13201-bib-0054","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2010.32.9110","article-title":"Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes","volume":"29","author":"Xu","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510341395900_onco13201-bib-0055","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/6\/523\/41918866\/oncolo_25_6_523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/6\/523\/41918866\/oncolo_25_6_523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:35:05Z","timestamp":1640428505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/6\/523\/6443459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,12,24]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0574","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,1]]},"published":{"date-parts":[[2019,12,24]]}}}